Kristen Pierce, MD
University of Vermont
4
4
4
N/A
0
0
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (4)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Anna Durbin, MD
Center for Immunization Research, Johns Hopkins School of Public Health
Shared therapeutic areas:
Worked with same sponsors:
Anna Durbin, MD
Center for Immunization Research (CIR), Johns Hopkins School of Public Health
Shared therapeutic areas:
Worked with same sponsors:
Alberto Santiago-Cornier, MD
Department of Molecular Medicine
Shared therapeutic areas:
Jose Tavarez-Valle, MD
Private Practice, PR
Shared therapeutic areas:
Ana Maria B de Filippis, PhD
Oswaldo Cruz Foundation (Flavivirus Diagnostic and Reference Laboratory- Rio de Janeiro)
Shared therapeutic areas:
Worked with same sponsors:
Luis Rodriguez-Carrasquillo, MD
Private Practice, PR
Shared therapeutic areas:
Myrielle Dupont-Rouzeyrol, PhD
Institut Pasteur de Nouvelle-Calédonie
Shared therapeutic areas:
Beth Kirkpatrick, MD
University of Vermont
Shared therapeutic areas:
Worked with same sponsors:
Clemente Diaz-Perez, MD
University of PR
Shared therapeutic areas:
Nigel Hill, PhD
London School of Hygiene and Tropical Medicine
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (4)
Showing 4 of 4 trials
Safety and Immunogenicity of the Live Attenuated Zika Vaccine rZIKV/D4Δ30-713 in Flavivirus-naïve Adults
Evaluating the Safety and Protective Efficacy of a Single Dose of a Trivalent Live Attenuated Dengue Vaccine to Protect Against Infection With DENV-2
Evaluating the Safety, Tolerability, and Immunogenicity of a Tetravalent Dengue Vaccine (V180) in Healthy Adults Who Previously Received a Live-Attenuated Tetravalent Vaccine (TV003 or TV005)
Evaluation of the Safety and Immunogenicity of rDEN3Δ30, a Live Attenuated Monovalent Dengue Virus Vaccine
All 4 trials loaded